InAADR

Protein Information

Protein Name: Sodium channel protein type 5 subunit alpha (Q14524)
Gene Name: SCN5A
Description:
PDB ID: 2KBI
Protein Family: PF00520
Protein Category: Ion Channels

This panel provides drug-protein interaction and their ADRs along with references

Interacting Drugs Toxicity Mechanism Reference
Amiodarone Sudden Cardiac Death Sudden cardiac death due to long-QT syndrome [ ADR Type 2 ] Genetic and molecular basis of cardiac arrhythmias: impact on clinical management parts I and II
Atenolol Sudden Cardiac Death Sudden cardiac death due to long-QT syndrome [ ADR Type 2 ] Genetic and molecular basis of cardiac arrhythmias: impact on clinical management parts I and II
Covera Sudden Cardiac Death Sudden cardiac death due to long-QT syndrome [ ADR Type 2 ] Genetic and molecular basis of cardiac arrhythmias: impact on clinical management parts I and II
Diltiazem Sudden Cardiac Death Sudden cardiac death due to long-QT syndrome [ ADR Type 2 ] Genetic and molecular basis of cardiac arrhythmias: impact on clinical management parts I and II
Flecainide Sudden Cardiac Death Sudden cardiac death due to long-QT syndrome [ ADR Type 2 ] Genetic and molecular basis of cardiac arrhythmias: impact on clinical management parts I and II
Hydrochlorothiazide Sudden Cardiac Death Sudden cardiac death due to long-QT syndrome [ ADR Type 2 ] Genetic and molecular basis of cardiac arrhythmias: impact on clinical management parts I and II
Mexiletine Sudden Cardiac Death Sudden cardiac death due to long-QT syndrome [ ADR Type 2 ] Genetic and molecular basis of cardiac arrhythmias: impact on clinical management parts I and II
Moricizine Sudden Cardiac Death Sudden cardiac death due to long-QT syndrome [ ADR Type 2 ] Genetic and molecular basis of cardiac arrhythmias: impact on clinical management parts I and II
Pacerone Sudden Cardiac Death Sudden cardiac death due to long-QT syndrome [ ADR Type 2 ] Genetic and molecular basis of cardiac arrhythmias: impact on clinical management parts I and II
Procainamide Sudden Cardiac Death Sudden cardiac death due to long-QT syndrome [ ADR Type 2 ] Genetic and molecular basis of cardiac arrhythmias: impact on clinical management parts I and II
Pronestyl Sudden Cardiac Death Sudden cardiac death due to long-QT syndrome [ ADR Type 2 ] Genetic and molecular basis of cardiac arrhythmias: impact on clinical management parts I and II
Propafenone Sudden Cardiac Death Sudden cardiac death due to long-QT syndrome [ ADR Type 2 ] Genetic and molecular basis of cardiac arrhythmias: impact on clinical management parts I and II
Propranolol Sudden Cardiac Death Sudden cardiac death due to long-QT syndrome [ ADR Type 2 ] Genetic and molecular basis of cardiac arrhythmias: impact on clinical management parts I and II
Quinidine Sudden Cardiac Death Sudden cardiac death due to long-QT syndrome [ ADR Type 2 ] Genetic and molecular basis of cardiac arrhythmias: impact on clinical management parts I and II
Sotalol Sudden Cardiac Death Sudden cardiac death due to long-QT syndrome [ ADR Type 2 ] Genetic and molecular basis of cardiac arrhythmias: impact on clinical management parts I and II
Terfenadine Sudden Cardiac Death Sudden cardiac death due to long-QT syndrome [ ADR Type 2 ] Genetic and molecular basis of cardiac arrhythmias: impact on clinical management parts I and II
Testosterone Propionate Weight Increased Not Available Large-scale prediction and testing of drug activity on side-effect targets
Tikosyn Sudden Cardiac Death Sudden cardiac death due to long-QT syndrome [ ADR Type 2 ] Genetic and molecular basis of cardiac arrhythmias: impact on clinical management parts I and II
Tocainide Sudden Cardiac Death Sudden cardiac death due to long-QT syndrome [ ADR Type 2 ] Genetic and molecular basis of cardiac arrhythmias: impact on clinical management parts I and II
Toprol XL Sudden Cardiac Death Sudden cardiac death due to long-QT syndrome [ ADR Type 2 ] Genetic and molecular basis of cardiac arrhythmias: impact on clinical management parts I and II
verapamil Sudden Cardiac Death Sudden cardiac death due to long-QT syndrome [ ADR Type 2 ] Genetic and molecular basis of cardiac arrhythmias: impact on clinical management parts I and II

This panel provides information on drug category

Toxicity Source
Apnoea Large-scale prediction and testing of drug activity on side-effect targets
Arrhythmias A novel SCN5A arrhythmia mutation, M1766L, with expression defect rescued by mexiletine
Bundle Branch Block Right A novel SCN5A mutation associated with idiopathic ventricular fibrillation without typical ECG findings of Brugada syndrome
Cardiac Arrest Large-scale prediction and testing of drug activity on side-effect targets
Central Nervous System Stimulation Large-scale prediction and testing of drug activity on side-effect targets
Coma Large-scale prediction and testing of drug activity on side-effect targets
Corneal Disorder Large-scale prediction and testing of drug activity on side-effect targets
Death Large-scale prediction and testing of drug activity on side-effect targets
Diplopia Large-scale prediction and testing of drug activity on side-effect targets
Dysarthria Large-scale prediction and testing of drug activity on side-effect targets
Foetal Damage Large-scale prediction and testing of drug activity on side-effect targets
Heart Disease Perioperative management of patients with Brugada syndrome
Hypoaesthesia Oral Large-scale prediction and testing of drug activity on side-effect targets
Impaired Healing Large-scale prediction and testing of drug activity on side-effect targets
Keratitis Large-scale prediction and testing of drug activity on side-effect targets
Loss Of Consciousness Large-scale prediction and testing of drug activity on side-effect targets
Methaemoglobinaemia Large-scale prediction and testing of drug activity on side-effect targets
Muscle Twitching Large-scale prediction and testing of drug activity on side-effect targets
Myocardial Depression Large-scale prediction and testing of drug activity on side-effect targets
Nervousness Large-scale prediction and testing of drug activity on side-effect targets
Nystagmus Large-scale prediction and testing of drug activity on side-effect targets
Presyncope Large-scale prediction and testing of drug activity on side-effect targets
Respiratory Failure Large-scale prediction and testing of drug activity on side-effect targets
Sensitisation Large-scale prediction and testing of drug activity on side-effect targets
Syncope Antiarrhythmic effect of IKr activation in a cellular model of LQT3
Tinnitus Large-scale prediction and testing of drug activity on side-effect targets
Tremor Large-scale prediction and testing of drug activity on side-effect targets
Ventricular Fibrillation Large-scale prediction and testing of drug activity on side-effect targets
Ventricular Tachycardia Antiarrhythmic effect of IKr activation in a cellular model of LQT3
Vision Blurred Large-scale prediction and testing of drug activity on side-effect targets

InAADR: Drug-Protein-ADRs database